El año pasado, Beigene Ltd generó 5.28B USD en su segmento con mejor rendimiento, Product. United States realizó la mayor aportación, representando 2.88B USD el año pasado. Para el último trimestre, Beigene Ltd reportó unos ingresos de 1.64B USD para el periodo finalizado el 2026-06-30, procedentes del segmento con mejor rendimiento, Product. United States aportó los mayores ingresos, alcanzando los 914.21M USD.

Por negocio

Ingresos operativos

Proporción

Anual

Anual

Trimestral

Product

BRUKINSA

Tislelizumab

XGEVA

BLINCYTO

REVLIMID

KYPROLIS

POBEVCY

Other

Other Collaboration

Right to access intellectual property revenue

Research and development service revenue

Material rights revenue

VIDAZA

Pamiparib

License revenue

Collaboration

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

Product

5.28B(50.00%)

3.72B(49.40%)

2.15B(46.61%)

1.22B(46.24%)

603.00M(33.89%)

308.87M(100.00%)

222.60M(51.98%)

130.88M(66.03%)

BRUKINSA

3.93B(37.19%)

2.64B(35.12%)

1.29B(28.02%)

564.65M(21.44%)

217.99M(12.25%)

--(--)

Tislelizumab

737.30M(6.98%)

620.84M(8.25%)

536.62M(11.65%)

422.88M(16.06%)

255.12M(14.34%)

--(--)

XGEVA

305.98M(2.90%)

224.40M(2.98%)

92.83M(2.02%)

63.40M(2.41%)

45.96M(2.58%)

--(--)

BLINCYTO

104.22M(0.99%)

74.33M(0.99%)

54.34M(1.18%)

36.11M(1.37%)

12.52M(0.70%)

--(--)

REVLIMID

83.69M(0.79%)

36.03M(0.48%)

76.02M(1.65%)

79.05M(3.00%)

70.06M(3.94%)

--(--)

KYPROLIS

74.97M(0.71%)

66.17M(0.88%)

39.80M(0.86%)

13.70M(0.52%)

--(--)

POBEVCY

47.40M(0.45%)

53.51M(0.71%)

56.55M(1.23%)

38.12M(1.45%)

1.35M(0.08%)

--(--)

Other

--(--)

60.04M(0.80%)

22.67M(0.49%)

16.03M(0.61%)

7.74M(0.44%)

--(--)

Other Collaboration

--(--)

30.70M(0.41%)

13.04M(0.28%)

9.49M(0.36%)

--(--)

Right to access intellectual property revenue

--(--)

104.48M(2.27%)

104.99M(3.99%)

3.98M(0.22%)

--(--)

Research and development service revenue

--(--)

79.43M(1.72%)

46.82M(1.78%)

53.67M(3.02%)

--(--)

Material rights revenue

--(--)

71.98M(1.56%)

--(--)

VIDAZA

--(--)

13.96M(0.30%)

15.21M(0.58%)

19.59M(1.10%)

--(--)

Pamiparib

--(--)

6.67M(0.14%)

5.46M(0.21%)

3.66M(0.21%)

--(--)

License revenue

--(--)

484.65M(27.24%)

--(--)

Collaboration

--(--)

205.62M(48.02%)

67.33M(33.97%)

Por región

Ingresos operativos

Proporción

Anual

Anual

Trimestral

United States

China

Europe

ROW

PRC

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

FY2017

United States

2.88B(53.91%)

1.96B(51.37%)

1.13B(45.89%)

502.63M(35.50%)

495.26M(42.10%)

18.23M(5.90%)

134.69M(31.45%)

42.79M(21.59%)

138.42M(58.07%)

China

1.68B(31.43%)

1.41B(37.04%)

--(--)

Europe

611.37M(11.44%)

362.63M(9.52%)

202.01M(8.22%)

--(--)

ROW

171.81M(3.22%)

78.81M(2.07%)

26.59M(1.08%)

73.26M(5.17%)

163.84M(13.93%)

--(--)

71.97M(16.81%)

23.04M(11.62%)

75.54M(31.69%)

PRC

--(--)

1.10B(44.82%)

840.03M(59.33%)

517.17M(43.97%)

290.65M(94.10%)

221.56M(51.74%)

132.38M(66.79%)

24.43M(10.25%)